AMRX - Mergers and acquisitions

- Provides the clinical benefits of baclofen in rapidly dissolvable granule formulation with flexible dosing for individual patient needs Amneal Pharmaceuticals, Inc. (NYSE:AMRX) ("Amneal" or the "Company") today announced the commercial launch of LYVISPAH®, a baclofen oral granules (5, 10 and 20 mg) specialty product approved by the U.S. Food and Drug Administration ("FDA") for the treatment of spasticity related to multiple sclerosis and other spinal cord disorders. LYVISPAH is bioequivalent to oral baclofen tablets and provides flexible, customized dosing with 5mg, 10mg and 20mg single-dose packets of granules. The rapidly dissolving flavored granules provide an alternative for patient

- Expands Amneal's Neurology Presence into Spasticity Amneal Pharmaceuticals, Inc. (NYSE:AMRX) ("Amneal") and Saol Therapeutics, a private specialty pharmaceutical company ("Saol"), today announced a definitive agreement under which Amneal will acquire Saol's Baclofen franchise, including Lioresal® and LYVISPAHTM as well as a pipeline product under development. The acquisition expands Amneal's commercial institutional and specialty portfolio in neurology while adding commercial infrastructure in advance of its entry into the biosimilar institutional market. The transaction is expected to be accretive to Amneal's adjusted EBITDA and adjusted earnings per share results for 2022. Lioresal® i